Aquestive Therapeutics

AQST

Market cap $771M

Aquestive Therapeutics, Inc. ( AQST ) Discusses Anaphylm Regulatory Progress, Commercial Strategy, and Pipeline Development November 6, 2025 12:00 PM EST Company Participants Daniel Barber - CEO, President & Director Melina Cioffi - Senior Vice President of Regulatory Affairs Cassie Jung - Chief Operating Officer Gary Slatko - Interim Chief Medical Officer Sherry Korczynski - Chief Commercial Officer Ernie Toth - Chief Financial Officer Conference Call Participants David Amsellem - Piper Sandler & Co., Research Division Presentation David Amsellem Piper Sandler & Co., Research Division All right. Well, good afternoon, everyone.

Aquestive Therapeutics, Inc. ( AQST ) Q3 2025 Earnings Call November 6, 2025 8:00 AM EST Company Participants Daniel Barber - CEO, President & Director Ernie Toth - Chief Financial Officer Sherry Korczynski - Chief Commercial Officer Gary Slatko - Interim Chief Medical Officer Conference Call Participants Brian Korb David Amsellem - Piper Sandler & Co., Research Division Rick Miller - Cantor Fitzgerald & Co., Research Division Raghuram Selvaraju - H.C. Wainwright & Co, LLC, Research Division Andreas Argyrides - Oppenheimer & Co. Inc., Research Division François Brisebois - LifeSci Capital, LLC, Research Division Jason Butler - Citizens JMP Securities, LLC, Research Division Denis Reznik - Raymond James & Associates, Inc., Research Division James Molloy - Alliance Global Partners, Research Division Presentation Operator Good day, and thank you for standing by.

Although the revenue and EPS for Aquestive Therapeutics (AQST) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Aquestive Therapeutics (AQST) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.13 per share a year ago.

WARREN, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that it will report results for the third quarter ended September 30, 2025 and provide an update on recent developments in its business after market close on Wednesday, November 5, 2025.

Here is how Aquestive Therapeutics (AQST) and Arcturus Therapeutics (ARCT) have performed compared to their sector so far this year.

Aquestive Therapeutics leverages its PharmFilm® platform to develop Anaphylm, a sublingual epinephrine film targeting a $1B+ U.S. market. AQST's management, including former EpiPen marketing leadership, and a recent $85M equity raise position the company for a strong commercial launch. Base case projections see Anaphylm capturing 15–25% market share, supporting an $8–$20 per-share valuation if launch and adoption succeed.

Aquestive Therapeutics (AQST) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

WARREN, N.J., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the United States Patent and Trademark Office (USPTO) has issued two additional U.S. patents related to Anaphylm, the Company's novel epinephrine prodrug sublingual film.

Aquestive Therapeutics (AQST) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.